PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 10, 2026Communications Biology0 citationsOpen Access

OSBPL3 drives colorectal cancer progression via Hippo-YAP signaling and modulates MEK inhibitor sensitivity

YZYuchen ZhongCZChaojing ZhengJMJiajie Ma

Key Points

  • The research aims to identify the role of OSBPL3 in colorectal cancer progression via Hippo-YAP signaling.
  • Analyzed clinical specimens for OSBPL3 expression levels.
  • Used experimental models to evaluate the impact of OSBPL3 depletion and overexpression on cancer cell behavior.
  • Conducted mechanistic studies to assess the interaction between OSBPL3 and 14-3-3 proteins.
  • Investigated the effects of YAP1 suppression on MEK inhibitor resistance in patient-derived organoids.
  • OSBPL3 levels are elevated in colorectal cancer tissues, correlating with poor patient survival.
  • Depleting OSBPL3 reduces cancer cell proliferation and invasion and causes cell cycle arrest.
  • Overexpressing OSBPL3 accelerates tumor growth.
  • Tumors with high OSBPL3 expression show resistance to MEK inhibitors, which can be reversed by YAP1 suppression.

Abstract

Colorectal cancer progression involves dysregulated signaling pathways such as Hippo-YAP, but upstream regulators remain poorly defined. Here we demonstrate that oxysterol-binding protein-like 3 (OSBPL3) modulates Hippo-YAP signaling to drive tumor aggressiveness. Analysis of clinical specimens and experimental models shows that elevated OSBPL3 levels in colorectal cancer tissues correlate with shortened patient survival. Depleting OSBPL3 impairs cancer cell proliferation and invasion and induces cell cycle arrest, while its overexpression accelerates tumor growth. Mechanistic studies reveal that OSBPL3 binds 14-3-3 proteins to promote YAP1 nuclear translocation, activating downstream oncogenic pathways. Notably, tumors with high OSBPL3 expression exhibit resistance to MEK inhibitors, but this resistance is overcome by YAP1 suppression or combined YAP/MEK inhibition in patient-derived organoids. These results establish OSBPL3 as a critical Hippo-YAP pathway regulator and propose targeting OSBPL3-mediated signaling as a therapeutic strategy for colorectal cancers with Hippo pathway alterations.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Zhong et al. (2026) studied this question.

synapsesocial.com/papers/69af951a70916d39fea4c5aehttps://doi.org/10.1038/s42003-026-09811-8
Ask AI
Helpful
Bookmark
Share
View Full Paper